초록

○ 방사선육종 두류(아피오스, 렌틸, 기능성두류) 추출물 획득 및 대사체 분리/구조분석 완료
○ 추출물 및 지표성분 활용 염증 및 대사성질환 생리활성 평가 완료
○ 방사선육종 차조기로부터 신규 화합물 분리 및 구조분석 완료
○ 방사선육종 차조기 추출물의 기술이전 완료(관절염 개선 효능)
○ 방사선육종 국화 품종을 이용한 대사체 분리/항산화 활성 평가 및 티백 시제품 제조

(출처 : 보고서 요약서 3p)

Abstract ▼

Ⅳ. Results
1. Isolation of metabolite and investigation for physiological activity from radiation mutant Apio
A. Isolation and structural analysis of metabolite from radiation mutant Apio
- Isolation and structural analysis of 20 metabolites from ethyl acetate and butanol extracts of rad

Ⅳ. Results
1. Isolation of metabolite and investigation for physiological activity from radiation mutant Apio
A. Isolation and structural analysis of metabolite from radiation mutant Apio
- Isolation and structural analysis of 20 metabolites from ethyl acetate and butanol extracts of radiation mutant Apios
- Conformation of structure by NMR
B. Evaluation of physiological activity of metabolite from radiation mutant Apio
- 4 compounds among isolated 20 compounds had shown anti-inflammatory activity
- 2 compounds among isolated 20 compounds had shown inhibitory activity for alpha-glucosidase
- AP7 had 50% inhibitory activity at 50 μM for DPP-IV
C. Evaluation of mechanism for anti-inflammatory activity of lupinalbin A isolated from radiation mutant Apio
- Lupinalbin A inhibited the production of iNOS mRNA and protein in a dose dependent manner
- Lupinalbin A inhibited the production of IL-6, TNF-α, MCP-1iNOS in a dose dependent manner
- Lupinalbin A inhibited the production of IFN-beta and STAT1 protein

2. Acquisition of extracts and investigation of physiological activity from soybean bred mutant lines
A. Acquisition of extracts from 150 soybean bred mutant lines and development of analysis condition for LC/MS
- Development of optimal analysis condition for UPLC/ELSA and UPLC/Q-tof. MS using 11 standard compounds
- Development of preprocessing condition for LC/MS using soybean bred lines
B. Development of molecular networking condition and LC/MSMS analysis using soybean bred 45 mutant lines
- Development of optimal molecular networking condition via structural similarity uisng 11 standard compounds
- Conformation of structural information of metabolites contained into extracts by LC/MS analysis results
C. Multivariate statistical techniques
- Evaluation of difference between wild type and mutant soybean line using the PCA, PLS-DA, and HCA
D. Evaluation of regulatory activity for metabolic disease of 150 soybean bred mutant lines
- Investigation about whether the extract of 150 soybean bred mutant lines can inhibit the activity of alpha-glucosidase and DPP-IV enzyme
- There were no mutant lines showed inhibitory activity

3. Acquisition of extracts and investigation of physiological activity from radiation mutant lentil
A. Acquisition of extracts and isolation of compounds from lentil
- Acquisition of ethnolic extracts and solvent extracts from lentil
- Isolation of 5 metabolites from butanolic extract from lentil
B. Investigation of physiological activity of lentil extracts and components
- 4 compounds among isolated 5 compounds had shown inhibitory activity for TBK-1 enzyme in a dose dependent manner
- 3 compounds among isolated 5 compounds had shown inhibitory activity for both alpha-glucosidase and DPP-IV enzyme in a dose dependent manner
C. Analysis of molecular docking
- 3 compounds shown inhibitory activity for DPP-IV has good position for DPP-IV S1 and S2. And all flavone core was mainly positioned into S1, furthermore glycoside of that was correlated with S2

4. Follow-up study for development of functional food using radiation mutant Perilla extracts
A. Acquisition of supercritical carbon dioxide extracts and isolation of compounds from mutant Perilla and wild type
- Acquisition of supercritical carbon dioxide extracts from mutant and wild type Perilla dried leaves
- Isolation of 9-hydroxy isoegomaketone (New compound) from mutant Perilla extract and isolation of myristicin from wild type Perilla extract
- The contents of 4 monoterpene compounds was analyzed between mutant and wild type Perilla extracts
B. Investigation of anti-inflammatory activity of new compound (1)
- New compounds had shown inhibitory activity for NO production in LPS-induced RAW264.7 cells
C. Investigation of anti-arthritic activity of mutant Perilla extract on CIA model
- Clinical arthritis scoring and paw thickness was statistically reduced in the group treated by mutant Perilla extract
- The level of IL-1beta in blood was statistically reduced in the group treated by mutant Perilla extract
- Conformation of anti-arthritic effect of mutant Perilla extract (133 mg/kg/day) in a CIA animal model
D. Analysis of toxicology of mutant Perilla extract by single oral administration
- In the case of female rat, ALD (approximate lethal dose) was 1,000 mg/kg. And in male rat, ALD was between 1,000 mg/kg and 2,000 mg/kg
E. Analysis of toxicology of mutant Perilla extract by 14-day repeated oral administration
- In the case of female rat, MTD (maximum tolerated dose) was above 150 mg/kg. And in male rat, MTD was above 300 mg/kg/day
- The target organ of mutant Perilla extracts was supposed the thymus and spleen
F. Carry out the technological transfer using mutant Perilla extract
- Completion of technological trasnfer
- Company: SFC Bio
- Fixed amount: 200,000,000(KW, containing milestone 170,000,000)

5. Development of method for isolation of new compound from mutant Perilla
A. Isolation of new compounds using centrifugal partition chromatography (CPC)
- Isolation of three compounds (9-hydroxy-isoegomaketone (1), isoegomaketone (2), Perillaketone (3)) from mutant Perilla extract
B. Determination of distribution coefficient (K), isolation coefficient (α), and solvent system for the CPC isolation condition
- Determination of K and α using various solvent condition
- Descending mode-> n-hexane:ethyl acetate:ethanol:water = 5:5:5:5
- Ascending mode-> n-hexane:ethyl acetate:ethanol:water = 8:2:8:2
C. Isolation of compounds using CPC
- Isolation of 9-hydroxy-isoegomaketone (2.4mg, 96.7% purity) using descending mode
- Isolation of isoegomaketone (56.1mg, 97.6% purity) and perillaketone(78.6mg, 96.1% purity) using ascending mode

6. Follow-up study for development of anti-oxidant food using radiation mutant Chrysanthemum cultiva
A. Acquisition of extract from ARTI-dark chocolate, nobel wine, and natural one
- Acquisition of ethanolic extract from three
- Acquistion of solvent extract from ARTI-dark chocolate
B. Investigation of anti-oxidant activity using the extracts of ARTI-dark chocolate, nobel wine, and natural one
- ARTI-dark chocolate has highest anti-oxidant activity among three using ABTS and DPPH assay
C. Isolation of compounds from ARTI-dark chocolate
- Isolation 7 compounds from ethylacetate extracts of ARTI-dark chocolate
D. Comparison of the compounds among the extracts from ARTI-dark chocolate, noble wine, and natural one
- ARTI-dark chocolate contained more flavonoid and phenolic compounds than noble wine and natural one, however contained less flavonoid aglycone than those

7. Comparative study between commercial Chrysanthemum tea and ARTI-dark chocolate tea via leaching temperature and time
A. Production of tea prototype using ARTI-dark chocolate
- Production of tea prototype using ARTI-dark chocolate using low-temp method (Temp 15℃, moisture 20%)
B. Acquisition of extracts via leaching temperature and time, comparative study for anti-oxidant activity
- Tea (1g) was leached by 75℃, 100℃ for 2 min, 4 min respectively
- The tea made by ARTI-dark chocolate had shown more anti-oxidant activity that commercial Chrysanthemum tea in DPPH assay

(출처 : SUMMARY 12p)

목차 Contents

• 표지 ... 1
• 제 출 문 ... 2
• 보고서 요약서 ... 3
• 요 약 문 ... 4
• SUMMARY ... 11
• CONTENTS ... 17
• 목차 ... 19
• 제1장 연구개발과제의 개요 ... 22
• 제1절. 연구개발 목적 ... 22
• 1. 최종목표 ... 22
• 2. 연구개발 주요내용 ... 22
• 제2절. 연구개발 필요성 및 범위 ... 22
• 제2장 국내외 기술개발 현황 ... 24
• 제1절. 국내 기술개발 현황 ... 24
• 제2절. 국외 기술개발 현황 ... 25
• 제3장 연구개발수행 내용 및 결과 ... 27
• 제1절. 연구개발 내용 및 결과 ... 27
• 1. 방사선육종 아피오스 추출물 획득 및 대사체 분리/구조분석 ... 27
• 2. 방사선육종 아피오스 추출물에서 분리된 대사체의 생리활성 분석 ... 33
• 3. 방사선육종 두류 추출물 확보 및 생리활성 평가 ... 40
• 4. 방사선육종 렌틸 추출물 확보 및 생리활성 평가 ... 57
• 5. 렌틸로부터 분리된 플라보노이드 배당체에 대한 대사성질환 효능 평가 ... 63
• 6. 방사선육종 차조기 포함 추출복합물을 이용한 관절염 개선 기능성식품 개발에 대한 후속 연구 ... 67
• 7. 방사선육종 차조기로부터 분리된 신규화합물 대량 분리법 개발 ... 82
• 8. 방사선육종 국화 품종을 이용한 항산화 기능성식품 개발에 대한 후속 연구 ... 88
• 9. 방사선육종 국화 품종 (아티다크초콜렛)과 시판중인 국화차 티백의 침출 온도 및 시간에 따른 비교 연구 ... 95
• 제4장 목표달성도 및 관련분야에의 기여도 ... 104
• 제1절. 연구개발 목표 달성도 ... 104
• 제2절. 기술발전 기여도 ... 105
• 제5장 연구개발결과의 활용계획 ... 107
• 제1절. 추가연구 필요성 ... 107
• 제2절. 타 연구 응용 및 기업화 추진방안 ... 107
• 제6장 연구개발과정에서 수집한 해외과학기술정보 ... 108
• 제7장 참고문헌 ... 111
• 연구성과(연구사업지원시스템 입력성과) ... 113
• 끝페이지 ... 118